Table 1.

Duration of hemolysis and transfusion requirement in 27 patients with PLS post AHSCT.

	Patient Characteristic		Hemolysis
References	Age	Dx	Start Date	Resolution Date	Days Total	RBC Units Transfused
Hows, J. et al. Blood 1986;67:177–181	17	CGL	10	15	6	9
	13	CGL	16	22	7	6
	24	SAA	10	19	10	14
	11	AML	9	18	10	7
	26	ALL	11	14	4	6
	32	SAA	9	16	8	5
Toren, A. et al. Blood 1996;87:843–4	12	ALL	8	14	7	7
Greeno, E.W. et al. Transfusion 1996;36:71–4	37	CML	7	22	16	16
Bornhauser, M. et al. BMT 1997;19:295–7	23	CML	12	17	6	10
Oziel-Taieb, S. et al. BMT 1997;19:1155–6	38	MM	8	18	11	12
Moog, R. et al. Beitr Infus Trans 1997;34:150–2	19	AML	9	16	8	NR
Laurencet, F.M. et al. Hematol Cell Ther 1997;39:159–62	37	MM	12	22	11	9
Salmon, J.P. et al. Transfusion 1999;39:824–7	16	AML	7	13	7	NR
Leo, A. et al. Transfusion 2000;40:632–6	50	AML	17	24	8	10
Tiplady, C.W. et al. Transfus Med 2001;11:455–8	28	ALL	9	14	6	17
Bolan, C.D. et al. Br J Hematol 2001;112:787–95	55	CLL	8	16	9	6
	38	AML	6	13	8	8
	38	NHL	10	13	4	9
Hoegler, W. et al. Med Pediatr Oncol 2002;38:143–4	7	ALL	8	17	10	7
Worel, N. et al. Transfusion 2002;42:1293–301	35	ALL	9	22	14	NR
	33	AML	10	21	12	NR
	47	NHL	7	25	19	NR
	42	AML	8	11	4	NR
Reed, M. et al. Arch Pathol Lab Med 2003;127:1366–8	61	AML	NR	NR	NR	NR
Noborio, K. et al. Leuk Lymphoma 2003;44:357–9	35	CTCL	8	12	5	NR
Curtin, N.J. et al. Leuk Lymphoma 2005;27:206–8	54	TPLL	11	22	12	8
Nair, V. et al. BMT 2007;39:805–6	13	ALL	12	18	7	31